Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Don Whitley announces distribution arrangement with Cell Biosciences
All equipment sales activities will pass to Cell Biosciences, with all equipment service and...
$50m donation for new endometriosis research institute
Three generations of the philanthropic Ainsworth family have committed a total of $50 million...
New directory, funding to support WA life science sector
The WA Government has announced an online directory for the state's life science sector, as...
